Xilio Therapeutics

Xilio develops tumor-selective immunotherapies using blocking domains to minimize toxicity and target treatment to the tumor microenvironment.
Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2021
Stage of Initial Investment
Series C
Initial Investment Year
2021